title: Combined excision and intralesional bevacizumab for sebaceous carcinoma of the eyelid in an Amur tiger (Panthera tigris altaica).
abstract: An 18-year-old zoo-kept female Amur tiger presented with an approximately 5 mm diameter lateral canthal eyelid mass in the left eye which grossly appeared red and irregular. The mass was completely excised via lateral canthoplasty. Histopathologic evaluation was consistent with a diagnosis of sebaceous cell carcinoma, which is a potentially aggressive cutaneous neoplasm. The sebaceous carcinoma recurred within 3 months and slowly increased in size until a second surgical excision was performed 9 months following the first surgery. The second surgical excision was combined with intralesional injection of 10 mg of the antiangiogenic drug bevacizumab. Histology confirmed the diagnosis. The tiger was euthanized 16 months postoperatively for reasons unrelated to, and without recurrence of, the eyelid neoplasm. At postmortem, no gross periocular or metastatic lesions were noted, and histopathology of the lateral canthus provided no evidence of recurrence. Surgical excision combined with intralesional bevacizumab treatment induced life-long resolution of the sebaceous carcinoma. Bevacizumab treatment may be associated with the regression of periocular angiogenic proliferative conditions, including neoplasia, by inhibiting angiogenesis.
authors.affiliation: New Bolton Center, University of Pennsylvania School of Veterinary Medicine, 382 Street Road, Kennett Square, PA 19348, USA.
authors.forename: Michele L
authors.initials: ML
authors.lastname: Edelmann
authors.forename: Mary L
authors.initials: ML
authors.lastname: Utter
authors.forename: Lin V
authors.initials: LV
authors.lastname: Klein
authors.forename: Kathryn L
authors.initials: KL
authors.lastname: Wotman
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D000836:Animals, Zoo; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D002277:Carcinoma / Q000188:drug therapy / Q000601:surgery / Q000662:veterinary*; D005142:Eyelid Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000662:veterinary*; D005260:Female; D036502:Infusions, Intralesional; D046010:Tigers
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab